Brian Gadbaw

1.1k total citations
15 papers, 773 citations indexed

About

Brian Gadbaw is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Brian Gadbaw has authored 15 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Brian Gadbaw's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Hemoglobinopathies and Related Disorders (5 papers) and Acute Myeloid Leukemia Research (3 papers). Brian Gadbaw is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Hemoglobinopathies and Related Disorders (5 papers) and Acute Myeloid Leukemia Research (3 papers). Brian Gadbaw collaborates with scholars based in United States, France and Italy. Brian Gadbaw's co-authors include Paul M. Sondel, Jacquelyn A. Hank, Stephen D. Gillies, Jacek Gan, John M. Maris, Kenneth B. DeSantes, Wendy B. London, Robert C. Seeger, Suzanne Shusterman and Ralph A. Reisfeld and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Brian Gadbaw

15 papers receiving 762 citations

Peers

Countries citing papers authored by Brian Gadbaw

Since Specialization

Citations

This map shows the geographic impact of Brian Gadbaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Gadbaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Gadbaw more than expected).

Fields of papers citing papers by Brian Gadbaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Gadbaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Gadbaw. The network helps show where Brian Gadbaw may publish in the future.

Co-authorship network of co-authors of Brian Gadbaw

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Gadbaw. A scholar is included among the top collaborators of Brian Gadbaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Gadbaw. Brian Gadbaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects 2019 ·Cancer Chemotherapy and Pharmacology ·Vassilios Aslanis, Kenichi Umehara, Felix Huth, Taoufik Ouatas, (unknown), Andrew A. Butler, Wen Zhou, Brian Gadbaw	18
2	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies 2018 ·Annals of Hematology ·Jean‐Jacques Kiladjian, Paola Guglielmelli, Martin Grießhammer, Güray Saydam, Tamás Masszi, Simon Durrant, Francesco Passamonti, Mark M. Jones, Hui‐Ling Zhen, Jingjin Li, Brian Gadbaw, Julian Perez Ronco, Md Mahmudul Hasan Khan, Srđan Verstovšek	18
3	Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials 2018 ·Immunotherapy ·Madan Jagasia, Robert Zeiser, Michael Arbushites, (unknown), Brian Gadbaw, Nikolas von Bubnoff	54
4	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study 2017 ·Annals of Hematology ·Alessandro M. Vannucchi, Srđan Verstovšek, Paola Guglielmelli, Martin Grießhammer, Timothy C. Burn, Ahmad Naim, Dilan Paranagama, Mahtab Marker, Brian Gadbaw, Jean‐Jacques Kiladjian	64
5	Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly 2017 ·International Journal of Hematology ·Keita Kirito, Kenshi Suzuki, Koichi Miyamura, Masahiro Takeuchi, Hiroshi Handa, Shinichiro Okamoto, Brian Gadbaw, Kyosuke Yamauchi, (unknown), Kazuo Itô, Masayuki Hino	12
6	Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study 2016 ·Blood ·Yeşim Aydınok, Zeynep Karakaş, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Norbert Hollaender, (unknown), Brian Gadbaw, Alì Taher	8
7	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues 2015 ·Drug Design Development and Therapy ·Edward M. Wolin, Barbara Jarząb, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David R. Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Li Jiang, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell‐Price, Wasat Mansoor, Kjell Öberg	150
8	Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study 2015 ·Blood ·Jean‐Jacques Kiladjian, Tamás Masszi, Mark M. Jones, Brian Gadbaw, Jingjin Li, Dany Habr, Alessandro M. Vannucchi, Srđan Verstovšek	1
9	The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial 2015 ·Blood ·Carole B. Miller, Jean‐Jacques Kiladjian, Martin Grießhammer, Ahmad Naim, William Sun, Brian Gadbaw, Srđan Verstovšek, Alessandro M. Vannucchi	2
10	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors 2013 ·Investigational New Drugs ·Sunil Sharma, Joachim Beck, Monica Mita, Sofia Paul, Margaret M. Woo, Margaret Squier, Brian Gadbaw, H. Miles Prince	29
11	Phase II trial of hu14.18-IL2 for patients with metastatic melanoma 2012 ·Cancer Immunology Immunotherapy ·Mark R. Albertini, Jacquelyn A. Hank, Brian Gadbaw, (unknown), (unknown), Heidi Schalch, Jacek Gan, KyungMann Kim, Jens C. Eickhoff, Stephen D. Gillies, Paul M. Sondel	65
12	Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface 2011 ·Cancer Immunology Immunotherapy ·Jennifer A. A. Gubbels, Brian Gadbaw, Ilia N. Buhtoiarov, Sachi Horibata, Arvinder Kapur, Dhara Patel, Jacquelyn A. Hank, Stephen D. Gillies, Paul M. Sondel, Manish S. Patankar, Joseph P. Connor	34
13	Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface Jennifer A. A. GubbelsBrian GadbawIlia N. BuhtoiarovSachi Horibata • Arvinder K. KapurDhara PatelJacquelyn A. HankStephen D. Gillies • Paul M. SondelManish S. PatankarJoseph Connor 2011 ·Brian Gadbaw, Paul M. Sondel, Ilia N. Buhtoiarov, Jacquelyn A. Hank, Stephen D. Gillies, Manish S. Patankar, Joseph P. Connor	1
14	Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy 2010 ·Cancer Research ·David Delgado, Jacquelyn A. Hank, Jill Kolesar, David Lorentzen, Jacek Gan, Songwon Seo, KyungMann Kim, Suzanne Shusterman, Stephen D. Gillies, Ralph A. Reisfeld, Richard K. Yang, Brian Gadbaw, Kenneth B. DeSantes, Wendy B. London, Robert C. Seeger, John M. Maris, Paul M. Sondel	136
15	Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study 2010 ·Journal of Clinical Oncology ·Suzanne Shusterman, Wendy B. London, Stephen D. Gillies, Jacquelyn A. Hank, Stephan D. Voss, Robert C. Seeger, C. Patrick Reynolds, Jennifer Kimball, Mark R. Albertini, (unknown), Jacek Gan, Jens C. Eickhoff, Kenneth B. DeSantes, Susan L. Cohn, Toby T. Hecht, Brian Gadbaw, Ralph A. Reisfeld, John M. Maris, Paul M. Sondel	181

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact